FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979691736> ?p ?o ?g. }

• W2979691736 endingPage "828" @default.
• W2979691736 startingPage "828" @default.
• W2979691736 abstract "Abstract Recurrent, heterozygous, somatic mutations in components of the mRNA spliceosome complex were recently identified in over 60% of myelodysplastic syndrome (MDS) patients. Splicing factor mutations are thought to be founding mutations in MDS based on their allele fraction at diagnosis. Splicing factor 3b Subunit 1 (SF3B1) is the most frequently mutated splicing factor in MDS. SF3B1 mutations are highly associated (70 – 85% of cases) with refractory anemia with ring sideroblasts (RARS), a morphologic subtype of MDS characterized by the presence of erythroid precursors with perinuclear iron-laden mitochondria in the bone marrow. The pathophysiological role of SF3B1 mutations in MDS has yet to be elucidated. To explore the biology of SF3B1 mutations, we generated a heterozygous conditional knock-in mouse model of the most common SF3B1 mutation, K700E. Heterozygous conditional knock-in of Sf3b1K700E leads to a progressive macrocytic anemia, with normal absolute neutrophil and platelet counts. Over the course of 15 months, mutant mice developed a statistically significant macrocytic anemia (hemoglobin of 11.4 g/dL vs. 14 g/dL, p = 0.004; MCV of 63.1 fL vs. 58.4 fL, p = 0.008) associated with elevated plasma erythropoietin levels (257.5 pg/mL vs. 101 pg/mL, p = 0.0016). Analysis of hematopoietic stem and progenitor cells at 12 and 65 weeks after induction showed a similar percentage of stem (LT-HSC, ST-HSC, MPP, LSK) and progenitor (LK, CMP, GMP, MEP, pre CFU-E) cells in Sf3b1K700E and wild-type animals. Histopathologic analysis revealed no significant difference in spleen weights, but increased erythroid islands in the red pulp of mutant animal spleens; suggestive of ineffective erythroid maturation. Sf3b1K700E animals have a normocellular bone marrow with rare ring sideroblasts. No ring sideroblasts were identified in wild-type controls. No overt hematological malignancies were identified during the observation period, however two mutant animals succumbed to significant anemia (2 of 11, 18%) compared to zero deaths in the wild-type controls. To further characterize the erythroid-specific phenotype observed in Sf3b1K700E mice, mutant and wild-type animals were treated with phenylhydrazine, a drug that induces intravascular hemolysis. Sf3b1K700E mice had a more rapid onset of anemia and a higher reticulocytosis during count recovery compared to wild-type controls. Analysis of the bone marrow and spleens was notable for a higher percentage of immature erythroid precursors (R2/basophilic erythroblasts) and a lower percentage of more mature erythroid precursors (R4/orthochromatophilic erythroblasts) in mutant animals, consistent with impaired erythroid maturation. An in vitro erythroid differentiation assay using purified ckit+ progenitor cells from Sf3b1K700E mice yielded significantly fewer erythroblasts (p = 0.0226) when compared to cells from wild type mice due to a statistically significant increase in the percentage of mutant cells in G0 (p=0.018). Similarly, noncompetitive transplantation assays highlighted the cell intrinsic nature of these erythroid-specific findings, as mutant cells did not show a defect in repopulating recipients, however Sf3b1K700E recipients developed a progressive macrocytic anemia. Competitive transplantation assays demonstrated a competitive disadvantage in Sf3b1K700E hematopoietic stem cells. Engraftment was lower in Sf3b1K700E compared to wild-type recipients 4 weeks (33.9% vs. 54.4%, p = 0.002) and 16 weeks (29% vs. 62.4%, p = 0.0013) after transplantation. These findings are consistent with the fact that RARS patients have a lower risk of progression to acute myeloid leukemia compared with other MDS subtypes. Taken together, our results demonstrate that heterozygous mutations in Sf3b1 lead to aberrant erythroid maturation and ineffective hematopoiesis in mice. These findings are consistent with the clinical picture seen in RARS patients. The results from the competitive transplantation studies may be consistent with the more favorable prognosis seen in patients with RARS, as our data suggest that additional genetic or epigenetic alterations must be acquired in SF3B1K700E cells to facilitate the development of clonal dominance. Disclosures No relevant conflicts of interest to declare." @default.
• W2979691736 created "2019-10-18" @default.
• W2979691736 creator A5015102296 @default.
• W2979691736 creator A5051427859 @default.
• W2979691736 creator A5059417641 @default.
• W2979691736 creator A5065765372 @default.
• W2979691736 creator A5070668676 @default.
• W2979691736 creator A5073561254 @default.
• W2979691736 creator A5081137671 @default.
• W2979691736 creator A5088194956 @default.
• W2979691736 creator A5091858318 @default.
• W2979691736 date "2014-12-06" @default.
• W2979691736 modified "2023-09-28" @default.
• W2979691736 title "Mutant Splicing Factor 3b Subunit 1 (SF3B1) Causes Dysregulated Erythropoiesis and a Stem Cell Disadvantage" @default.
• W2979691736 doi "https://doi.org/10.1182/blood.v124.21.828.828" @default.
• W2979691736 hasPublicationYear "2014" @default.
• W2979691736 type Work @default.
• W2979691736 sameAs 2979691736 @default.
• W2979691736 citedByCount "3" @default.
• W2979691736 countsByYear W29796917362015 @default.
• W2979691736 countsByYear W29796917362016 @default.
• W2979691736 countsByYear W29796917362021 @default.
• W2979691736 crossrefType "journal-article" @default.
• W2979691736 hasAuthorship W2979691736A5015102296 @default.
• W2979691736 hasAuthorship W2979691736A5051427859 @default.
• W2979691736 hasAuthorship W2979691736A5059417641 @default.
• W2979691736 hasAuthorship W2979691736A5065765372 @default.
• W2979691736 hasAuthorship W2979691736A5070668676 @default.
• W2979691736 hasAuthorship W2979691736A5073561254 @default.
• W2979691736 hasAuthorship W2979691736A5081137671 @default.
• W2979691736 hasAuthorship W2979691736A5088194956 @default.
• W2979691736 hasAuthorship W2979691736A5091858318 @default.
• W2979691736 hasConcept C104317684 @default.
• W2979691736 hasConcept C109159458 @default.
• W2979691736 hasConcept C153911025 @default.
• W2979691736 hasConcept C201750760 @default.
• W2979691736 hasConcept C2022786 @default.
• W2979691736 hasConcept C203014093 @default.
• W2979691736 hasConcept C2780007613 @default.
• W2979691736 hasConcept C28328180 @default.
• W2979691736 hasConcept C501734568 @default.
• W2979691736 hasConcept C502942594 @default.
• W2979691736 hasConcept C54355233 @default.
• W2979691736 hasConcept C54458228 @default.
• W2979691736 hasConcept C67705224 @default.
• W2979691736 hasConcept C86803240 @default.
• W2979691736 hasConceptScore W2979691736C104317684 @default.
• W2979691736 hasConceptScore W2979691736C109159458 @default.
• W2979691736 hasConceptScore W2979691736C153911025 @default.
• W2979691736 hasConceptScore W2979691736C201750760 @default.
• W2979691736 hasConceptScore W2979691736C2022786 @default.
• W2979691736 hasConceptScore W2979691736C203014093 @default.
• W2979691736 hasConceptScore W2979691736C2780007613 @default.
• W2979691736 hasConceptScore W2979691736C28328180 @default.
• W2979691736 hasConceptScore W2979691736C501734568 @default.
• W2979691736 hasConceptScore W2979691736C502942594 @default.
• W2979691736 hasConceptScore W2979691736C54355233 @default.
• W2979691736 hasConceptScore W2979691736C54458228 @default.
• W2979691736 hasConceptScore W2979691736C67705224 @default.
• W2979691736 hasConceptScore W2979691736C86803240 @default.
• W2979691736 hasIssue "21" @default.
• W2979691736 hasLocation W29796917361 @default.
• W2979691736 hasOpenAccess W2979691736 @default.
• W2979691736 hasPrimaryLocation W29796917361 @default.
• W2979691736 hasRelatedWork W1506037097 @default.
• W2979691736 hasRelatedWork W1596202309 @default.
• W2979691736 hasRelatedWork W1968618554 @default.
• W2979691736 hasRelatedWork W1992928173 @default.
• W2979691736 hasRelatedWork W2042325586 @default.
• W2979691736 hasRelatedWork W2073889874 @default.
• W2979691736 hasRelatedWork W2091242855 @default.
• W2979691736 hasRelatedWork W2144892629 @default.
• W2979691736 hasRelatedWork W2355025828 @default.
• W2979691736 hasRelatedWork W2407055687 @default.
• W2979691736 hasRelatedWork W2410105580 @default.
• W2979691736 hasRelatedWork W2415380211 @default.
• W2979691736 hasRelatedWork W2549241580 @default.
• W2979691736 hasRelatedWork W2554900558 @default.
• W2979691736 hasRelatedWork W2560009908 @default.
• W2979691736 hasRelatedWork W2594234018 @default.
• W2979691736 hasRelatedWork W2614118562 @default.
• W2979691736 hasRelatedWork W2979574081 @default.
• W2979691736 hasRelatedWork W2993905496 @default.
• W2979691736 hasRelatedWork W3137920913 @default.
• W2979691736 hasVolume "124" @default.
• W2979691736 isParatext "false" @default.
• W2979691736 isRetracted "false" @default.
• W2979691736 magId "2979691736" @default.
• W2979691736 workType "article" @default.